| Item type |
文献 / Documents(1) |
| 公開日 |
2020-10-26 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s00262-016-1915-5 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1007/s00262-016-1915-5 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma |
|
言語 |
en |
| タイトル別表記 |
|
|
その他のタイトル |
Cancer Immunol Immunother |
|
言語 |
en |
| 著者 |
オバラ, ワタル
カラシマ, タカシ
タケダ, カズヨシ
カトウ, レンペイ
カトウ, ヨウイチロウ
カネヒラ, ミツグ
タカタ, リョウ
イノウエ, ケイジ
片桐, 豊雅
シュウイン, タロウ
ナカムラ, ユウスケ
フジオカ, トモアキ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Purpose
Through genome-wide expression profile analysis, hypoxia-inducible protein 2 (HIG2) has previously been identified as an oncoprotein involved in development/progression of renal cell carcinoma (RCC). We subsequently identified a highly immunogenic HLA-A*0201/0206-restricted epitope peptide (HIG2-9-4) corresponding to a part of HIG2 and applied it as a therapeutic vaccine. We conducted a phase I clinical trial using the HIG2-9-4 peptide for patients with advanced RCC.
Materials and Methods
Nine patients having HLA-A*0201 or HLA-A*0206 with metastatic or unresectable RCC after failure of the cytokine and/or tyrosine kinase inhibitor therapies were enrolled in this study. The patients received subcutaneous administration of the peptide as an emulsion form with Montanide ISA-51 VG once a week in a dose-escalation manner (doses of 0.5, 1.0, or 3.0 mg/body, 3 patients for each dose). The primary endpoint was safety, and the secondary endpoints were immunological and clinical responses.
Results
Vaccinations with HIG2-9-4 peptide could be well tolerated without any serious systemic adverse events. Peptide-specific cytotoxic T lymphocyte (CTL) responses were detected in eight of the nine patients. Doses of 1.0 or 3.0 mg/body seemed to induce a CTL response better than did a dose of 0.5 mg/body, although the number of patients was too small to draw a firm conclusion. The disease control rate (stable disease for ≥4 months) was 77.8 %, and the median progression-free survival time was 10.3 months.
Conclusions
HIG2-9-4 peptide vaccine treatment was tolerable and effectively induced peptide-specific CTLs in RCC patients. This novel peptide vaccine therapy for RCC is promising. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cancer peptide vaccine |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Genome-wide expression profile |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cytotoxic T lymphocyte |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Renal cell carcinoma |
| 書誌情報 |
en : Cancer Immunology, Immunotherapy
巻 66,
号 1,
p. 17-24,
発行日 2016-10-18
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03407004 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
14320851 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00598499 |
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| EID |
|
|
識別子 |
321073 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
cii_66_1_17.pdf (805 KB)
.png)
